The recent SCIL‐STROKE and SCIL‐SAH trials (Subcutaneous Interleukin‐1 Receptor Antagonist in Ischemic Stroke and aneurysmal SAH, respectively) two small single‐center double‐blind randomized phase 2 trials, demonstrated the efficacy of subcutaneous IL‐1Ra administration in reducing the peripheral inflammatory response, evaluated by plasma IL‐6 and CRP levels, in acute ischemic stroke and SAH, respectively (Galea et al, 2018; Smith et al, 2018). Here, IL6 is linked to ischemic stroke.